Drug combination provides 43% improvement in time to disease progression

The U.S. FDA has approved a new treatment option for myeloma patients who have relapsed or who have not responded to at least one other course of treatments. The combination of DOXIL® with VELCADE® provides nearly a three month improvement in time to disease progression as compared to VELCADE alone, which is a 43% improvement in response according to a phase III multi-national clinical trial.

"This is an important new combination for patients, especially those with resistant myeloma, because of the VELCADE/DOXIL synergy – VELCADE increases the sensitivity of cancer cells to DOXIL and DOXIL does the same for VELCADE," said Brian G.M. Durie, M.D., chairman and co-founder of the IMF. "The growing success treating myeloma and extending patients' lives is due in large part to new drugs that can be used in combination and in sequence, and the approval of the new VELCADE/DOXIL combination fits perfectly into that strategy."

DOXIL is a specially (liposomal) formulated version of the chemotherapy agent doxorubicin, and is approved for use in other forms of cancer. VELCADE, bortezomib, is approved for myeloma patients who have relapsed or not responded to a previous course of treatment. VELCADE/DOXIL may be used with or without steroids, providing patients with a steroid-free alternative.